Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 ...
As with other drugs, Bavencio (avelumab) can cause side effects, such as fatigue or muscle and bone pain. If you’re not able to tolerate side effects of Bavencio, talk with your doctor or ...
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status. Among patients with advanced urothelial carcinoma, ...
The JAVELIN Ovarian 200 study was testing Bavencio (avelumab) alone or in combination with chemotherapy (pegylated doxorubicin) in patients with resistant or refractory ovarian cancer, but who ...
Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback